|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael Snape, PhD, says when identifying promising therapeutic targets for any disease or condition, including developmental disorders such as Fragile X syndrome, PMS, CDM1, and Rett syndrome, it is critical researchers work to understand the mechanism of disease and disease pathways as well as the unmet need and patient experience.
|
|
|
Sridhar Krishnan, Pii’s Senior Vice President, Operations and Strategic Initiatives, discusses how manufacturing is not solely where Pii wanted to be, so the company made a concerted effort to get back to its CDMO roots.
|
|
|
Siddhartha De, PhD, and Peter Vanderslice, PhD, present their research on the use of proprietary, orally available compounds that can activate the immune system to enhance the effectiveness of vaccines as well as immuno-oncology therapies for cancer, especially in patient populations that are most vulnerable to disease.
|
|
|
Olivia Merkel, PhD, and Christoph Zimmermann, PhD student, discuss the benefits of microfluidic encapsulation technology for gene silencing applications in cancer immunology and inflammatory diseases, where siRNA can potentially be used to downregulate genes associated with these pathologies.
|
|
|
|
|
|
|
|
|

Pharmaceutical formulators continue to strive to create market leading products with maximum efficacy, quality, and performance. However, the inability to achieve a high level of API solubility and stability are common day-to-day challenges which limit product success. With the help from Croda’s superior quality and high purity line of specialty excipients, formulators are able to surpass these barriers, making Croda the supplier of choice in the global pharmaceutical market. With products being manufactured at multiple sites throughout the world, we are able to provide a consistent, local supply of a vast range of high purity surfactants, lipids, and other chemical specialties. Click here for more.
|
|
|
|
|
|
 |
|
PCI Pharma Services recently announce a new milestone in its global Clinical footprint with the expansion of cold chain clinical supply storage and distribution capabilities at its….
|
|
 |
|
Pfizer Inc. and BioNTech SE recently announced the European Medicines Agency (EMA) approved storage of COMIRNATY at -25°C to -15°C for a total of 2 weeks….
|
|
 |
|
Researchers at the Hospital General Manuel Gea González in Mexico City have reported results from a study designed to assess the impact of four specific strains of probiotics on the rate of remission from infection with SARS-CoV-2….
|
|
 |
|
Agios Pharmaceuticals, Inc. recently announced its shareholders voted to approve the previously disclosed sale of its commercial, clinical, and research-stage oncology portfolio to….
|
|
|
|
|
Upcoming eNewsletter Features:
April 7 – Excipients
April 14 – Prefilled Syringes
|
|
|
|
|
|
|
|